MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa’s clinical ...

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader... By Investing.com • Apr 28, 2025 ...

The partnership – which has seen a $150 million upfront payment from Novartis alongside a pledge for up to $2.1 billion in milestones – gives the Swiss pharma group rights to Monte Rosa's VAV1 ...

Nirmal Suchanti, Founder of Concept and one of the pioneers of financial services ads and PR in India, is no more. He was 81. In a heartfelt post, his son, Vivek Suchanti, Chairman & Managing ...

Monte Rosa's in-house pipeline is led by MRT-2359, a molecular glue degrader that breaks down a protein called GSPT1 and is in phase 1/2 trials as a potential treatment for lung cancer and other ...

We cover the latest Monte Rosa Therapeutics headlines and breaking news impacting Monte Rosa Therapeutics stock performance. Investing.com - Financial Markets Worldwide Open in App ...

Monte Rosa Therapeutics reported sales of The Monte Rosa Therapeutics EPS (TTM) is 0.08. Monte Rosa Therapeutics reported sales of 84.93, net income of 46.89, and EPS of 0.57 for the latest ...

Review Monte Rosa Therapeutics Inc (GLUE:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Police said the minivan driver was a 44-year-old Santa Rosa man and that his three boys were occupants in the vehicle. The man, his 12-year-old, 11-year-old and 5-year-old were all seriously injured.

The 64th Monte-Carlo Television Festival was opened Friday by Prince Albert II of Monaco at a glitzy ceremony at the Grimaldi Forum.

Missouri-based Nostrum Laboratories and its founder and CEO Nirmal Mulye have agreed to pay a minimum of $3,825,000, ...

Learn about the executive team and board of directors at Monte Rosa Therapeutics Inc (GLUE:XNAS) and review their bios and compensation over the latest fiscal years.